SCHEMBL241593

SCHEMBL241593

O=C(c1ccc(N2[C@@H]3CC[C@H]2CC(Oc2ccccn2)C3)cc1)N1CCCC2CCCC=C21

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NAAA Q02083 1/20 0.37
HRH3 Q9Y5N1 2/20 0.37
ALDH1A1 P00352 2/20 0.36
OPRK1 P41145 3/20 0.35
KCNH2 Q12809 3/20 0.35
EPHX2 P34913 1/20 0.35
KMT2A Q03164 2/20 0.35
AXL P30530 1/20 0.35
TYRO3 Q06418 1/20 0.35
MERTK Q12866 1/20 0.35
NPC1 O15118 1/20 0.34
OPRM1 P35372 1/20 0.34
HCRTR1 O43613 1/20 0.34
HCRTR2 O43614 1/20 0.34
RIPK1 Q13546 1/20 0.34
KDM5A P29375 1/20 0.33
AVPR2 P30518 1/20 0.33
OXTR P30559 1/20 0.33
AVPR1A P37288 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL241592 0.78 HSD11B1 (0.46) NAAAHRH3OPRK1KCNH2EPHX2
SCHEMBL3456155 0.73 ALDH1A1 (0.52) ALDH1A1KMT2A
SCHEMBL237937 0.70 ALDH1A1 (0.42) ALDH1A1KMT2ANPC1
SCHEMBL240447 0.70 HSD11B1 (0.42) NAAAOPRK1KCNH2EPHX2KMT2A
SCHEMBL5946914 0.68 HPGD (0.54) ALDH1A1KMT2A
SCHEMBL240569 0.67 GAA (0.42) ALDH1A1KMT2A
SCHEMBL1355318 0.67 ADORA2A (0.61) ALDH1A1NPC1
SCHEMBL1393891 0.67 FFAR4 (0.41)
SCHEMBL12115345 0.67 EPHX2 (0.37) NAAAHRH3OPRK1KCNH2EPHX2
SCHEMBL241412 0.66 PARP10 (0.46) ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100292215-A1 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS HIGH POINT PHARMACEUTICALS, LLC (US) 2010-11-18 US claimed
US-20100009968-A1 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS HIGH POINT PHARMACEUTICALS, LLC (US) 2010-01-14 US claimed
EP-2044073-A1 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS High Point Pharmaceuticals, LLC (US) 2009-04-08 EP claimed
WO-2008006702-A1 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS HIGH POINT PHARMACEUTICALS, LLC. (US) 2008-01-17 WO claimed
US-8383668-B2 11-beta-hydroxysteroid dehydrogenase type 1 active compounds HIGH POINT PHARMACEUTICALS, LLC (US) 2013-02-26 US disclosed
US-20120010194-A1 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds HIGH POINT PHARMACEUTICALS, LLC (US) 2012-01-12 US disclosed
US-20120004209-A1 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds HIGH POINT PHARMACEUTICALS, LLC (US) 2012-01-05 US disclosed
US-8053447-B2 11β-hydroxysteroid dehydrogenase type 1 active compounds HIGH POINT PHARMACEUTICALS, LLC (US) 2011-11-08 US disclosed
US-8048908-B2 11β-hydroxysteroid dehydrogenase type 1 active compounds HIGH POINT PHARMACEUTICALS, LLC (US) 2011-11-01 US disclosed
US-20100292215-A1 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS HIGH POINT PHARMACEUTICALS, LLC (US) 2010-11-18 US disclosed
US-20100009968-A1 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS HIGH POINT PHARMACEUTICALS, LLC (US) 2010-01-14 US disclosed
EP-2044073-A1 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS High Point Pharmaceuticals, LLC (US) 2009-04-08 EP disclosed
WO-2008006702-A1 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS HIGH POINT PHARMACEUTICALS, LLC. (US) 2008-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004209-A1 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds HSD11B1, HSD3B1, HSD11B2 NAAA 2328/4885HRH3 1997/4885ALDH1A1 77/4885
US-20120010194-A1 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds HSD11B1, HSD11B2, HSD3B1 NAAA 1626/4885HRH3 1274/4885ALDH1A1 93/4885
US-20100009968-A1 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS HSD11B1, HSD17B1, HSD3B1 NAAA 2116/4885HRH3 1490/4885ALDH1A1 78/4885
US-20100292215-A1 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS HSD11B1, HSD3B1, HSD17B1 NAAA 2644/4885HRH3 2308/4885ALDH1A1 67/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.